New data from Gazi University illuminate research in breast cancer
2008 JAN 17 -- "The aim of this article was to investigate the efficacy of ultrasonography-guided core needle biopsy and prognostic factor analysis of breast cancer to plan overall treatment strategy. A consecutive series of nonpalpable and palpable breast cancers constituted our study group (n= 201 lesions; mean size, 20.4 mm) Mean number of core samples was 3.4," scientists in Ankara, Turkey report. "Malignant lesions diagnosed with core biopsy underwent therapeutic surgical excision. Core biopsy and surgical excisions were compared for histologic type, grade, estrogen receptors (ERs), progesterone receptors (PgRs), and c-erbB2 levels. Cutoff values for ER, PgR, and c-erbB2 affecting the management strategy were selected as 10%, 10%, and 50%, respectively. Eighty-five lesions (42.3%) were malignant in core biopsy (mean size, 18.4 mm). 1 Among these, 11 were inoperable and 13 were surgically excised at other institutions. In 61 lesions, core and surgical excision specimens were evaluated in the same institution (mean tumor size, 18.6 mm; range 6-60 mm). Concordance between the 2 biopsy methods was 85.2% (52 of 61) for histologic type of tumor, 1 68.8% (33 of 48) for tumor grade, 90% (27 of 30) for ER, 86.7% (26 of 30) for PgR, and 79.3% (23 of 29) for c-erbB2 levels. Appropriate site selection for sampling was indicated to be of paramount importance, I especially in determining reliable ER, PgR, and c-erbB2 levels. Core needle biopsy of breast cancer is equally effective compared wth surgical biopsy and can be used in overall treatment planning," wrote A. Ozdemir and colleagues, Gazi University. The researchers concluded: "However, appropriate site selection for sampling should be guaranteed using ultrasonographic guidance." Ozdemir and colleagues published their study in Clinical Breast Cancer (Can core biopsy be used instead of surgical biopsy in the diagnosis and prognostic factor analysis of breast carcinoma? Clinical Breast Cancer, 2007;7(10):791-795). For more information, contact A. Ozdemir, Gazi University, Dept. of Radiol, TR-06510 Ankara, Turkey. Publisher contact information for the journal Clinical Breast Cancer is: Cig Media Group, Lp, 3500 Maple Avenue, Ste. 750, Dallas, TX 75219-3931, USA. Keywords: Turkey, Ankara, Biopsy, Breast Cancer, Breast Carcinoma, Diagnosis, Diagnostics, Drugs, Hormones, Oncology, Pharmaceuticals, Progesterone, Surgery, Therapy, Treatment, Women's Health, Gazi University. This article was prepared by Women's Health Weekly editors from staff and other reports. Copyright 2008, Women's Health Weekly via NewsRx.com.
|
